The Oncology Institute Continues To Expect FY24 Revenue Of $400M - $415M, Est $414.66M; Cuts Gross Profit & Adjusted EBITDA Guidance
Portfolio Pulse from Benzinga Newsdesk
The Oncology Institute (TOI) has updated its full-year 2024 guidance, maintaining revenue expectations at $400M - $415M but cutting gross profit and adjusted EBITDA guidance due to slower than expected margin growth and the termination of a capitation contract.
August 13, 2024 | 9:14 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The Oncology Institute (TOI) maintains its FY24 revenue guidance at $400M - $415M but has cut its gross profit and adjusted EBITDA guidance due to slower margin growth and the termination of a capitation contract.
The maintenance of revenue guidance is positive, but the cut in gross profit and adjusted EBITDA guidance indicates financial challenges, likely leading to a negative short-term impact on TOI's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100